Head to head
Teladoc Health vs Veeva Systems
Side-by-side on the measures that matter, with a plain-English read. Full detail: TDOC · VEEV
TDOC
Teladoc Health
7.45-4.36%
1-year price shape — +10% over the period
Quant Rating C · 47/100
vs
VEEV
Veeva Systems
266.22+1.26%
1-year price shape — -2% over the period
Quant Rating C · 37/100
1-year performance, rebased to 100
Veeva Systems edges it on the scoreable measures. Veeva Systems earns the most per share.
| TDOC | VEEV | |
|---|---|---|
| Snapshot | ||
| Sector | Health Information Services | Health Information Services |
| Last price | 7.45 | 266.22 |
| Change today | -4.36% | +1.26% |
| 1-year return | +10.2% | -1.6% |
| Market cap | $1.36B | $43.10B |
| 52-week range | 4.40 – 9.89 | 148.05 – 325.99 |
| Valuation | ||
| P/E (TTM) | -8.66 | 43.64 |
| P/E percentile, own 5-yr range | 12th | 14th |
| P/B | 1.05 | 5.80 |
| Dividend yield | 0.00% | 0.00% |
| Profitability & growth | ||
| EPS (TTM) | -1.14 | 5.44 |
| Net profit (TTM) | $-207.81M | $880.78M |
| Revenue (TTM) | $2.47B | $3.46B |
| Provider revenue period date | 2026-09-29 | 2026-07-30 |
| Revenue growth (YoY) | -3.4% | +17.6% |
| Gross margin | 68.6% | 75.0% |
| Operating margin | -5.4% | 29.9% |
| Net margin | -6.3% | 29.3% |
| Free cash flow (TTM) | $126.12M | $1.67B |
| Provider cash-flow period date | 2026-09-29 | 2026-07-30 |
| Ownership & sentiment | ||
| Institutional ownership | 90.8% | 88.0% |
| Insider activity (12mo) | 13 buy / 34 sell | 25 buy / 22 sell |
| Short interest (% of float) | 17.7% | 2.4% |
| Analyst consensus | 33% buy / 58% hold / 8% sell (12) | 74% buy / 22% hold / 4% sell (23) |
| Analyst price target | $9 (+27%) | $320 (+20%) |
| StockVane view | ||
| StockVane Quant Rating | C (47) | C (37) |
| Company | ||
| Employees | 5,600 | 7,928 |
| Founded | 2002 | 2007 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.